AP20187 [195514-80-8]
Referentie T14299-25mg
Formaat : 25mg
Merk : TargetMol
AP20187 (Synonyms: B/B Homodimerizer)
AP20187
Copy Product InfoSynonyms B/B Homodimerizer
Cas No. 195514-80-8
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.80%
Appearance:Solid
Color:White
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | AP20187 (B/B Homodimerizer) is a cell-permeable compound used to dimerize FK506-binding protein (FKBP) fusion proteins, thereby initiating biological signaling cascades, gene expression, or disrupting protein-protein interactions. |
| In vitro | Treatment of LNCaP cells with AP20187 (B/B Homodimerizer) at a concentration of 100 nM significantly reduces ro-iCaspase-9 levels, while the smaller, processed, active form of caspase-9 becomes evident. |
| In vivo | Treatment with AP20187 significantly mitigates the effects of experimental autoimmune encephalomyelitis (EAE) on myelin sheaths in mice, markedly decreasing the prevalence of deteriorating axons and enhancing axonal density within demyelination sites in the lumbar spinal cord of PLP/Fv2E-PERK mice. Additionally, real-time PCR analysis reveals that AP20187 (B/B Homodimerizer) administration at doses of 0.5 mg/kg, 2 mg/kg, or 5 mg/kg notably elevates CHOP mRNA levels in the central nervous system (CNS) of PLP/Fv2E-PERK mice at post-infection day (PID) 12. |
| Synonyms | B/B Homodimerizer |
| Molecular Weight | 1482.75 |
| Formula | C82H107N5O20 |
| Cas No. | 195514-80-8 |
| Smiles | CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCC(CNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)CN(C)C)c1)c1cc(OC)c(OC)c(OC)c1 |
| Relative Density. | 1.192 g/cm3 (Predicted) |
| Storage | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (33.72 mM), Sonication is recommended.  Ethanol: 130 mg/mL (87.67 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.35 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Ethanol
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||